V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

KalVista Pharmaceuticals Executive Compensation (FY25)

KALV · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Benjamin Palleiko
Latest say-on-pay support
=
October 1, 2025
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The KalVista Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (10-K/A): April 30, 2026
9 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
KalVista Pharmaceuticals brief$1,500Get the executive brief
Velarion Member, one year
161 figures on this page: 154 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
KalVista Pharmaceuticals does not file an annual proxy statement (DEF 14A). Its executive compensation is disclosed directly in its Form 10-K (Part III), which is the filing cited throughout this document. A Form 10-K does not carry a disclosed compensation peer group; those sections are absent from this document for that reason, not from a data gap.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Benjamin Palleiko: $6,772,197 → $5,094,999 (24.8% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is KalVista Pharmaceuticals' chief executive and what were they paid?
Total compensation for Benjamin Palleiko, Chief Executive Officer, came to $5,094,999 in fiscal 2025. Palleiko's total was 24.8% lower than the $6,772,197 reported for fiscal 2024.
What was KalVista Pharmaceuticals' say-on-pay result?
For fiscal 2025, the say-on-pay proposal drew 89.4% support at the meeting held October 1, 2025.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
T. Andrew Crockett
Former Chief Executive Officer
◇◇◇◇——◇◇
Benjamin Palleiko
President, Chief Business Officer and Chief Financial Officer
◇◇◇◇——◇◇
Christopher Yea
Chief Development Officer
◇◇◇◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
T. Andrew Crockett
Former Chief Executive Officer
Departed during or after this year
◇◇◇◇——◇— not reconciled
Benjamin Palleiko
Chief Executive Officer
◇◇◇◇——◇◇
Paul Audhya
Chief Medical Officer
◇◇◇———◇◇
Christopher Yea
Chief Development Officer
◇◇◇◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Benjamin Palleiko
Chief Executive Officer
◇◇◇◇——◇◇
Paul Audhya
Chief Medical Officer
◇◇◇———◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Benjamin Palleiko
Chief Executive Officer
◇◇◇———◇◇
Paul Audhya
Chief Medical Officer
◇◇◇———◇◇
Brian Piekos
Chief Financial Officer
◇◇◇◇——◇◇
Bilal Arif
Chief Operating Officer
◇◇—◇———◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Benjamin PalleikoOTHER——————◇
Brian PiekosOTHER——————◇
Paul AudhyaOTHER——————◇
Fiscal 2022, 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Benjamin PalleikoRSU◇◇——
Option◇—◇5/17/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇5/25/2031
Option◇—◇5/16/2032
Paul AudhyaRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇4/30/2031
Option◇—◇5/16/2032
Brian PiekosRSU◇◇——
Option◇—◇5/17/2033
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brian J. G. Pereira
◇—◇———◇
Edward W. Unkart
◇—◇———◇
Nancy Stuart
◇—◇———◇
Laurence Reid
◇—◇———◇
Patrick Treanor
◇—◇———◇
William Fairey
◇—◇———◇
Benjamin L. Palleiko served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025October 1, 2025=◇◇◇
2024October 3, 2024=◇◇◇
2023October 3, 2024=◇◇◇
2022September 26, 2023=◇◇◇
2021October 13, 2022=◇◇◇
2020September 30, 2021=◇◇◇
2019October 1, 2020=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Benjamin Palleiko (Chief Executive Officer), FY2025 total compensation $5,094,999 (base salary $477,202) [exec_comp, SEC accession 0001193125-26-197556, filed 2026-04-30]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when KalVista Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact KalVista Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether KalVista Pharmaceuticals' disclosed peer group is defensible, who names KalVista Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
161 figures on this page: 154 cited to the filing that reported them, 7 calculated from figures it prints.
154 cited to the filing
7 calculated from the filing

Documents cited

  1. 0001193125-26-197556
    Summary Compensation Table
  2. 0001193125-25-227478
    Item 404(a) of Regulation S-K. Additionally, the Board has determined that Ms.
  3. 0001193125-25-185353
    DIRECTOR COMPENSATION · EXECUTIVE COMPENSATION · Summary Compensation Table
  4. 0000950170-24-112904
  5. 0001193125-24-205356
  6. 0000950170-23-050440
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0000950170-22-019610
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001564590-21-049879
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001564590-20-045741
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “KalVista Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/KALV (accessed 2026).
Short form: data: Velarion

The KalVista Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about KalVista Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy